4.6 Article

Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease

期刊

PLOS ONE
卷 13, 期 8, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0201991

关键词

-

向作者/读者索取更多资源

Background and aims In inflammatory bowel disease (IBD), the impact of established cardiovascular risk factors and disease-related factors on the risk of acute arterial events is still unclear. We aimed to identify risk factors of acute arterial events in patients with IBD. Methods All consecutive patients followed at Saint-Antoine Hospital between 1996 and 2015 with subsequent occurrence of acute arterial events (acute coronary syndrome or ischemic stroke) were identified. Traditional cardiovascular risk factors, treatment exposure, systemic inflammation (mean serum CRP level greater than or equal to 5 mg/L) and IBD clinical activity were assessed. A nested case-control study was performed including cases and controls without arterial ischemic event, matched on age, gender, and disease extent. Results A total of 30 patients (median age at acute vascular event occurrence: 42 years (interquartile range: 25-59)) developed acute coronary syndrome (n = 22) or ischemic stroke (n = 8). In univariate analysis, clinical disease activity and the persistence of systemic inflammation, diabetes, dyslipidemia and hypertension were significantly associated with an increased risk of acute arterial events. Neither protective nor aggravating effects associated with treatment exposure were identified. In multivariate analysis, the presence of diabetes (Odds ratio (OR): 14.5, 95% confidence interval (CI): 1.1-184.7) and clinical disease activity (OR: 10.4, 95% CI: 2.1-49.9) remained significantly associated with the risk of acute arterial event. Conclusion Disease activity may have an independent impact on the risk of acute arterial events in patients with IBD. These findings may highlight new potential benefits of optimizing anti-inflammatory treatment in patients with persisting clinical activity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Risk of Recurrent Acute Arterial Events Associated With Thiopurines and Anti-Tumor Necrosis Factor in Inflammatory Bowel Diseases

Lucile Dheyriat, Daniel Ward, Laurent Beaugerie, Tine Jess, Julien Kirchgesner

Summary: Patients with inflammatory bowel disease (IBD) are at increased risk of acute arterial events. The use of anti-tumor necrosis factor (anti-TNF) agents has a protective effect against the first occurrence of acute arterial events. In this study, the effect of anti-TNF and thiopurines on the risk of recurrent acute arterial events in IBD patients with a previous history of such events was assessed.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

Efficacy and safety of combination targeted therapies in immune-me diate d inflammatory disease: the COMBIO study

Lucas Guillo, Benoit Flachaire, Jerome Avouac, Catherine Dong, Maria Nachury, Guillaume Bouguen, Anthony Buisson, Ludovic Caillo, Mathurin Fumery, Cyrielle Gilletta, Xavier Hebuterne, Pierre Lafforgue, David Laharie, Emmanuel Mahe, Hubert Marotte, Stephane Nancey, Sebastien Ottaviani, Jean-Hugues Salmon, Guillaume Savoye, Melanie Serrero, Mathieu Uzzan, Manuelle Viguier, Christophe Richez, Laurent Peyrin-Biroulet, Philipe Seksik, Thao Pham

Summary: In a French multicenter cohort study, the effectiveness and safety of combination therapies (COMBIO) were assessed in patients with refractory/overlapping immune-mediated inflammatory diseases (IMIDs).

DIGESTIVE AND LIVER DISEASE (2023)

Article Gastroenterology & Hepatology

The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study

Aurelien Amiot, Jean-Francois Rahier, Filip Baert, Stephane Nahon, Ailsa Hart, Nikos Viazis, Livia Biancone, Eugeni Domenech, Catherine Reenears, Laurent Peyrin-Biroulet, Laurent Beaugerie, Johan Burisch

Summary: This study reports on the impact of the COVID-19 outbreak in patients with inflammatory bowel disease (IBD). The results show that the risk of COVID-19 and severe COVID-19 is not increased in IBD patients compared to the general population. There is also no negative impact of IBD-related medication on the risk of COVID-19 or severe COVID-19. Additionally, the COVID-19 outbreak led to a decrease in endoscopic and imaging procedures, but did not affect clinical activity and treatment.

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

Laurent Peyrin-Biroulet, Jean-Francois Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamas Molnar, Mark Lowenberg, Jonas Halfvarson, Edyta Zagorowicz, Helene Rousseau, Cedric Baumann, Filip Baert, Laurent Beaugerie

Summary: The I-CARE study aims to evaluate the benefit-risk ratio of current therapies in IBD patients. It collected data from 10,206 patients and observed the treatment risks of anti-tumor necrosis factor and other biologic therapies, particularly the risks of cancer/lymphoma and serious infections. The results showed that different treatment regimens had varying effects on patients, and further research is needed to assess specific risks.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival

Camille Danne, Chloe Michaudel, Jurate Skerniskyte, Julien Planchais, Aurelie Magniez, Allison Agus, Marie-Laure Michel, Bruno Lamas, Gregory Da Costa, Madeleine Spatz, Cyriane Oeuvray, Chloe Galbert, Maxime Poirier, Yazhou Wang, Alexia Lapiere, Nathalie Rolhion, Tatiana Ledent, Cedric Pionneau, Solenne Chardonnet, Floriant Bellvert, Edern Cahoreau, Amandine Rocher, Rafael Rose Arguello, Carole Peyssonnaux, Sabine Louis, Mathias L. Richard, Philippe Langella, Jamel El-Benna, Benoit Marteyn, Harry Sokol

Summary: Inflammatory bowel disease (IBD) is caused by a combination of genetic predisposition, gut microbiota dysbiosis, and environmental factors. Caspase recruitment domain 9 (Card9) is an IBD susceptibility gene that has been shown to protect against intestinal inflammation and fungal infection. However, the specific cell types and mechanisms involved in the CARD9 protective role against inflammation are still unknown.
Article Gastroenterology & Hepatology

Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases

Chloe Michaudel, Camille Danne, Allison Agus, Aurelie Magniez, Anne Aucouturier, Madeleine Spatz, Antoine Lefevre, Julien Kirchgesner, Nathalie Rolhion, Yazhou Wang, Aonghus Lavelle, Chloe Galbert, Gregory Da Costa, Maxime Poirier, Alexia Lapiere, Julien Planchais, Petr Nadvornik, Peter Illes, Cyriane Oeuvray, Laura Creusot, Marie-Laure Michel, Nicolas Benech, Anne Bourrier, Isabelle Nion-Larmurier, Cecilia Landman, Mathias L. Richard, Patrick Emond, Philippe Seksik, Laurent Beaugerie, Rafael Rose Arguello, David Moulin, Sridhar Mani, Zdenek Dvorak, Luis G. Bermudez-Humaran, Philippe Langella, Harry Sokol

Summary: This study identified a new mechanism linking tryptophan metabolism to intestinal inflammation and inflammatory bowel diseases (IBDs). Bringing back xanthurenic acid (XANA) and kynurenic acid (KYNA) has protective effects involving Aryl hydrocarbon Receptor (AhR) activation and the rewiring of cellular energy metabolism in intestinal epithelial cells and CD4(+) T cells. Manipulating the endogenous metabolic pathway with aminoadipate aminotransferase (AADAT) may provide new therapeutic strategies for correcting tryptophan metabolism alterations in IBD.
Article Multidisciplinary Sciences

Questioning the fetal microbiome illustrates pitfalls of low-biomass microbial studies

Katherine M. Kennedy, Marcus C. de Goffau, Maria Elisa Perez-Munoz, Marie-Claire Arrieta, Fredrik Backhed, Peer Bork, Thorsten Braun, Frederic D. Bushman, Joel Dore, Willem M. de Vos, Ashlee M. Earl, Jonathan A. Eisen, Michal A. Elovitz, Stephanie C. Ganal-Vonarburg, Michael G. Ganzle, Wendy S. Garrett, Lindsay J. Hall, Mathias W. Hornef, Curtis Huttenhower, Liza Konnikova, Sarah Lebeer, Andrew J. Macpherson, Ruth C. Massey, Alice Carolyn McHardy, Omry Koren, Trevor D. Lawley, Ruth E. Ley, Liam O'Mahony, Paul W. O'Toole, Eric G. Pamer, Julian Parkhill, Jeroen Raes, Thomas Rattei, Anne Salonen, Eran Segal, Nicola Segata, Fergus Shanahan, Deborah M. Sloboda, Gordon C. S. Smith, Harry Sokol, Tim D. Spector, Michael G. Surette, Gerald W. Tannock, Alan W. Walker, Moran Yassour, Jens Walter

Summary: The colonization of microbial communities in the human fetus and the prenatal intrauterine environment is still controversial. Recent studies analyzing microbial populations in human fetuses indicate that the detected signals might be due to contamination during sample collection or DNA sequencing processes. The presence of live and replicating microbial populations in healthy fetal tissues contradicts fundamental concepts in immunology and clinical microbiology. This has significant implications for our understanding of human immune development and highlights the challenges in studying microbial communities in low-biomass environments.

NATURE (2023)

Article Substance Abuse

Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice

Tetsuya Kouno, Suling Zeng, Yanhan Wang, Yi Duan, Sonja Lang, Bei Gao, Phillipp Hartmann, Noemi Cabre, Cristina Llorente, Chloe Galbert, Patrick Emond, Harry Sokol, Michael James, Chun Cheih Chao, Jian-Rong Gao, Mylene Perreault, David L. Hava, Bernd Schnabl

Summary: This study demonstrates that engineering gut bacteria to produce tryptophan metabolites can alleviate liver disease caused by alcohol through Ahr activation in intestinal immune cells.

ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH (2023)

Letter Gastroenterology & Hepatology

Letter: histologic disease activity and colorectal neoplasia risk-authors' reply

Julien Kirchgesner, Magali Svrcek

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post-inflammatory polyps

Thomas Wolf, Ayanna Lewis, Laurent Beaugerie, Magali Svrcek, Julien Kirchgesner, St Antoine IBD Network

Summary: In patients with inflammatory bowel disease, post-inflammatory polyps do not increase the risk of colorectal neoplasia after controlling for histologic activity.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Geriatrics & Gerontology

Impairment of aryl hydrocarbon receptor signalling promotes hepatic disorders in cancer cachexia

Adeline Dolly, Sarah A. Potgens, Morgane M. Thibaut, Audrey M. Neyrinck, Gabriela S. de Castro, Chloe Galbert, Camille Lefevre, Elisabeth Wyart, Silvio P. Gomes, Daniela C. Goncalves, Nicolas Lanthier, Pamela Baldin, Joshua R. Huot, Andrea Bonetto, Marilia Seelaender, Nathalie M. Delzenne, Harry Sokol, Laure B. Bindels

Summary: This study explores the potential role of the aryl hydrocarbon receptor (AHR) in cancer cachexia and finds that impaired AHR signaling contributes to hepatic inflammatory and metabolic disorders, exacerbating cachectic features. These findings provide innovative therapeutic strategies for cancer cachexia.

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2023)

Article Immunology

Staphylococcus epidermidis isolates from atopic or healthy skin have opposite effect on skin cells: potential implication of the AHR pathway modulation

Leslie Landemaine, Gregory Da Costa, Elsa Fissier, Carine Francis, Stanislas Morand, Jonathan Verbeke, Marie-Laure Michel, Romain Briandet, Harry Sokol, Audrey Gueniche, Dominique Bernard, Jean-Marc Chatel, Luc Aguilar, Philippe Langella, Cecile Clavaud, Mathias L. Richard

Summary: This study demonstrates that Staphylococcus epidermidis strains originating from healthy skin and atopic skin have different effects. Strains from atopic skin alter the structure of a 3D reconstructed skin model, while strains from healthy skin do not. The metabolites produced by strains from healthy skin can activate the aryl hydrocarbon receptor pathway, while strains from atopic skin cannot.

FRONTIERS IN IMMUNOLOGY (2023)

Article Microbiology

Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem

Madeleine Spatz, Gregory Da Costa, Rebecka Ventin-Holmberg, Julien Planchais, Chloe Michaudel, Yazhou Wang, Camille Danne, Alexia Lapiere, Marie-Laure Michel, Kaija-Leena Kolho, Philippe Langella, Harry Sokol, Mathias L. Richard

Summary: This study investigated the effects of antibiotic treatment on the fungal microbiota in the gut. It was found that amoxicillin-clavulanic acid treatment led to a decrease in the overall fungal population in mouse feces and a remodeling of the fungal community. Certain bacterial strains were shown to inhibit fungal growth. This study provides new insights into the interactions between fungi and bacteria in the gut and may offer new strategies for modulating gut microbiota equilibrium.

MICROBIOME (2023)

Review Microbiology

Targeting the gut microbiota in inflammatory bowel diseases: where are we?

Nicolas Benech, Harry Sokol

CURRENT OPINION IN MICROBIOLOGY (2023)

暂无数据